Rates have not been this low since 2022, but some homeowners may still be hesitant to jump back into the market.
One biotech firm raised more than $100 million and another generated more than $200 million in separate stock sales after their valuations soared on positive news for their lead drug candidates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results